- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT02916355
Role of Interleukin (IL)-1 in Postprandial Fatigue - The Chäschüechli 2 Study (Chäs2)
Role of IL-1 in Postprandial Fatigue - The Chäschüechli 2 Study
Role of IL-1 in postprandial fatigue - The Chäschüechli 2 Study It is a randomized, single dose, placebo-controlled, double blind, cross-over, proof-of-concept study.
16 healthy young men will be included in this study. The objective of this study is to evaluate if severity of postprandial fatigue is driven by IL-1.
Since fatigue is associated with increased cytokine levels, and since fatigue in chronic inflammatory settings, such as type 2 diabetes, can be reduced by inhibition of IL-1β, postprandial fatigue might also respond to anti-inflammatory intervention with IL-1 inhibition.
The aim of the study is to investigate whether postprandial fatigue is, at least in part, driven by the IL-1 system.
Studieoversikt
Studietype
Registrering (Faktiske)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiesteder
-
-
-
Basel, Sveits, CH-4031 Basel
- University Hospital Basel, Department of Endocrinology, Diabetes and Metabolism
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
Male subjects
- non-smoking
- apparently healthy
- BMI >18 and ≤28 kg/m2 or BMI >30 and ≤35 kg/m2
- Age 20-65 years
- Subject is usually eating breakfast and lunch
- Willingness to use contraceptive measures adequate to prevent the subject's partner from becoming pregnant during the study. Adequate contraceptive measures include hormonal methods used for two or more cycles prior to screening (e.g., oral contraceptive pills, contraceptive patch, or contraceptive vaginal ring), double barrier methods (e.g., contraceptive sponge, diaphragm used in conjunction with contraceptive foam or jelly, and condom used in conjunction with contraceptive foam or jelly), intrauterine methods (IUD) and sterilization (e.g., tubal ligation or a monogamous relationship with a vasectomized partner).
- Owner of a smartphone so they will be able to download and use the sleeping APP, Sleep cycle, prior to the study days.
Exclusion Criteria:
Subjects will be excluded from the study if they meet any of the following criteria:
- Night shift workers
- Subjects suffering from sleep disturbances
- Clinical signs of infection in the week before inclusion or history of infection during the last 2 months (CRP >5mg/l)
- Impaired fasting glucose (fasting plasma glucose >5.5mmol/l)
- Hematologic disease (leukocyte count < 1.5x109/l, hemoglobin <11 g/dl, platelets <100 x 103/ul)
- Kidney disease (creatinine > 1.5 mg/dl))
- Liver disease (transaminases >2x upper normal range)
- Heart disease
- Pulmonary disease
- Inflammatory disease
- History of carcinoma
- History of tuberculosis
- Alcohol consumption >40g/d
- Smoking
- Known allergy towards Kineret
- Known allergy to ingredients of the test meal
- Current treatment with any drug in the week before inclusion, including vitamin supplementation (especially vitamin C and E)
- Use of any investigational drug within 30 days prior to enrolment or within 5 half-lives of the investigational drug, whichever is longer
- Subject refusing or unable to give written informed consent
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Annen
- Tildeling: Randomisert
- Intervensjonsmodell: Crossover-oppdrag
- Masking: Dobbelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Eksperimentell: Normal BMI
Healthy young men, normal BMI (BMI >18 and ≤28 kg/m2) will receive interventions Anakinra and sodium Chloride (NaCl)
|
Subjects will receive Anakinra infusion and afterwards they will be fed a very fat containing meal, and postprandial fatigue will be measured regularly until 3,5 hour after the meal.
Andre navn:
subjects will receive NaCl infusion and afterwards they will be fed a very fat containing meal, and postprandial fatigue will be measured regularly until 3,5 hour after the meal.
Andre navn:
|
Eksperimentell: Overweight
Healthy young men (BMI >30 and ≤35 kg/m2) will receive interventions Anakinra and NaCl
|
Subjects will receive Anakinra infusion and afterwards they will be fed a very fat containing meal, and postprandial fatigue will be measured regularly until 3,5 hour after the meal.
Andre navn:
subjects will receive NaCl infusion and afterwards they will be fed a very fat containing meal, and postprandial fatigue will be measured regularly until 3,5 hour after the meal.
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
The primary outcome is change in fatigue measured by the SSS (Stanford Sleepiness Scale) between groups treated with Anakinra vs. placebo
Tidsramme: 7 to 9 days (change between study day 1 and study day 2)
|
Fatigue will be measured by using the SSS (Stanford Sleepiness Scale)
|
7 to 9 days (change between study day 1 and study day 2)
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Change in postprandial glucose, insulin, C-peptide, glucagon-like Peptide (GLP)-1(active/total), GIP(active/total), PYY, IL-6, tumor necrosis factor (TNF)-alfa, sCRP and cortisol due to any treatment (Anakinra vs. saline).
Tidsramme: 7 to 9 days (change between study day 1 and study day 2)
|
Blood sampling
|
7 to 9 days (change between study day 1 and study day 2)
|
Change in heart rate due to any treatment (Anakinra vs. saline)
Tidsramme: 7 to 9 days (change between study day 1 and study day 2)
|
Pulse watch
|
7 to 9 days (change between study day 1 and study day 2)
|
Change in insulin due to any treatment (Anakinra vs. saline).
Tidsramme: 7 to 9 days (change between study day 1 and study day 2)
|
Blood sampling
|
7 to 9 days (change between study day 1 and study day 2)
|
Change in C-peptide due to any treatment (Anakinra vs. saline).
Tidsramme: 7 to 9 days (change between study day 1 and study day 2)
|
Blood sampling
|
7 to 9 days (change between study day 1 and study day 2)
|
Change in GLP-1(active/total) due to any treatment (Anakinra vs. saline).
Tidsramme: 7 to 9 days (change between study day 1 and study day 2)
|
Blood sampling
|
7 to 9 days (change between study day 1 and study day 2)
|
Change in GIP(active/total) due to any treatment (Anakinra vs. saline).
Tidsramme: 7 to 9 days (change between study day 1 and study day 2)
|
Blood sampling
|
7 to 9 days (change between study day 1 and study day 2)
|
Change in PYY due to any treatment (Anakinra vs. saline).
Tidsramme: 7 to 9 days (change between study day 1 and study day 2)
|
Blood sampling
|
7 to 9 days (change between study day 1 and study day 2)
|
Change in IL-6 due to any treatment (Anakinra vs. saline).
Tidsramme: 7 to 9 days (change between study day 1 and study day 2)
|
Blood sampling
|
7 to 9 days (change between study day 1 and study day 2)
|
Change in TNF-alfa due to any treatment (Anakinra vs. saline).
Tidsramme: 7 to 9 days (change between study day 1 and study day 2)
|
Blood sampling
|
7 to 9 days (change between study day 1 and study day 2)
|
Change in sCRP due to any treatment (Anakinra vs. saline).
Tidsramme: 7 to 9 days (change between study day 1 and study day 2)
|
Blood sampling
|
7 to 9 days (change between study day 1 and study day 2)
|
Change in cortisol due to any treatment (Anakinra vs. saline).
Tidsramme: 7 to 9 days (change between study day 1 and study day 2)
|
Blood sampling
|
7 to 9 days (change between study day 1 and study day 2)
|
Samarbeidspartnere og etterforskere
Samarbeidspartnere
Etterforskere
- Hovedetterforsker: Marc Y Donath, MD, University Hospital, Basel, Switzerland
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- EKNZ BASEC 2016-00816
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Fethet
-
University Hospital, BrestFullført
-
Recep Tayyip Erdogan University Training and Research...FullførtVisceral Adiposity Index
-
Uşak UniversityFullførtPolycystisk ovariesyndrom | Visceral Adiposity IndexTyrkia